Cases
Solid Biosciences Inc. (SLDB)
Securities Class Action
Overview
Overview
- Date:
- 3/19/2018
- Company Name:
- Solid Biosciences, Inc.
- Stock Symbol:
- SLDB
- Status:
- Closed/Complete
NEW YORK, March 19, 2018 – Bragar Eagel & Squire, P.C. is investigating potential claims against Solid Biosciences Inc. (NASDAQ: SLDB). Our investigation concerns whether Myriad has violated the federal securities laws and/or engaged in other unlawful business practices. Our investigation concerns whether Solid Biosciences has violated the federal securities laws and/or engaged in other unlawful business practices.
On March 14, 2018, the Company announced it received notification from the U.S. Food and Drug Administration (FDA) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.
Following this news, shares of Solid Biosciences fell $16.99 per share, or over 64%, to close at $9.32 on March 15, 2018. Since the Company held its IPO on January 26, 2018, its stock price has fallen $6.83 per share, or over 42.5%, to close at $9.17 per share on March 19, 2018.
If you purchased or otherwise acquired Solid Biosciences shares and suffered a loss, continue to hold shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On March 14, 2018, the Company announced it received notification from the U.S. Food and Drug Administration (FDA) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in Duchenne muscular dystrophy (DMD), has been placed on Clinical Hold.
Following this news, shares of Solid Biosciences fell $16.99 per share, or over 64%, to close at $9.32 on March 15, 2018. Since the Company held its IPO on January 26, 2018, its stock price has fallen $6.83 per share, or over 42.5%, to close at $9.17 per share on March 19, 2018.
If you purchased or otherwise acquired Solid Biosciences shares and suffered a loss, continue to hold shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.